PHOENIX group

To whom this may concern, PHOENIX group welcomes the commitment of the European Commission to revise EU rules on medical devices and in vitro diagnostics. We especially welcome the focus of the targeted revision on protecting patient health whilst making the medical device sector more agile in a challenging global environment.

To whom this may concern, PHOENIX group welcomes the initiative of the European Commission to evaluate EU rules on medical devices and in vitro diagnostics. We especially welcome the focus of the evaluation on protecting patient health while making the medical device sector more agile in a challenging geopolitical environment.

To whom this may concern, Please find attached PHOENIX's group position on the Clean Corporate Vehicles. PHOENIX group remains available for any further questions from the Commission and looks forward to continuous engagement on this subject matter. Kind regards, Gavrilo Nikolic Head of Public Affairs

To whom this may concern, PHOENIX group is the largest European integrated healthcare provider with 224 sites in the business areas of pharmaceutical wholesale and pre-wholesale across 29 European countries and with more than 3,200 pharmacies in 17 European countries.

To whom it may concern, PHOENIX group welcomes the goal of the new Commissions term aimed at reducing administrative burden and making European business environment more competitive in the light of unprecedented geopolitical pressures. We further welcome the opportunity to share our position on the administrative burdens in environmental legislation.

To whom this may concern, PHOENIX group welcomes the fact that the Commission is continuing with its activities concerning uptake of Safe Hearts Plan. We especially welcome the fact that a specific recommendation will be proposed to Member States aimed at organizing screening for cardiovascular diseases (CVDs) tailored to their national healthcare systems.

To whom this may concern, On behalf of our daughter company, PXG Pharma, PHOENIX group is happy to share its position on the evaluation of Cosmetic Products Regulation with the Commission. Against this background, please find attached our contribution to the evaluation process.

To whom this may concern, PHOENIX group welcomes the Commissions initiative aimed at improving the cross-border circulation of media content and protecting viewers. To educate and inform patients about the patient-centered care they can receive in their local pharmacies, PHOENIX group uses influencer marketing on Instagram and TikTok in several markets where we are active with our pharmacy operations notably in…

To whom this may concern, PHOENIX group welcomes the European Commissions intension to simplify EU rules on direct taxation with the overarching goal of reducing administrative burden and inducing business growth across the EU. In our capacity as the largest distributor of critical medicines in Europe, we are highly qualified to contribute to this policy process and share our position (please see attached).

To whom it may concern, PHOENIX group welcomes the initiative of the European Commission to evaluate Regulation 2019/515 on the mutual recognition of goods lawfully marketed in another Member State of 19 March 2019.

To whom this may concern, PHOENIX group welcomes the initiative of the European Commission to evaluate the early implementation period of the Serious Cross-Border Threats to Heath Regulation. In our capacity as the largest European integrated healthcare provider with 224 sites in the business areas of pharmaceutical wholesale and pre-wholesale across 29 European countries and with more than 3,200 pharmacies in 17…